DEC 19, 2018 05:50 PM PST

Promising Drug for ALS?

WRITTEN BY: Nouran Amin

ALS, standing for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease affecting the nerve cells of the brain and the spinal cord. Current treatments for ALS work by slowing the progression of the disease however by only a few months. Now, research at the University of Alberta shows a promising drug that not only significantly slows the progression of the disease but can revolutionize treatment for ALS patients by extending and improving their quality of life.

Learn more about ALS:

The drug is called telbivudine and is used as a treatment for patients with hepatitis making it particularly safe as a promising therapeutic for ALS. "It is already proven safe to use in patients, and it has very good potential for repurposing to use in a new clinical setting against ALS," said Ted Allison, co-author of the study and associate professor in the Department of Biological Sciences.

In the research study published in Neurobiology of Disease, telbivudine was selected using computer simulations of most likely drug candidates before being tested on animal models. Specifically, the works by targeting a protein called SOD1. The protein was found to misfold and function improperly in ALS producing toxic effects that characterizes much of the phenotypic symptoms of the disease.

Credit: Medical News Today

"SOD1 is a protein that is known to misfold and misbehave in most cases of patients with ALS," says Allison. "We showed that telbivudine can greatly reduce the toxic properties of SOD1, including improving the health of the subject's motor neurons and improving movement."

However, because ALS is still not well understood by researchers and clinicians—promising therapeutics may take a while before being sent to clinical trials. But, this study provides one step closer.

“We don't yet know exactly what goes wrong first in the motor neurons or how the misbehaving SOD1 causes toxicity. Because there is still much to learn about the disease, the ALS research community focuses on both understanding ALS and on developing promising therapies,” explains lead author of the study—Michele DuVal.

Source: University of Alberta

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Do Nootropics Really Boost Brain Function?
  Nootropics are a broad range of both natural and artificial compounds though to improve cognitive function. Including everything from caffeine to Ad...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Does Adderall Really Work for People without ADHD?
Adderall is a popular stimulant. Known to treat Attention Deficit Disorder (ADHD), those without the condition also use it to increase attention, focus and...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Evolutionary-Busting Cancer Drug
Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhib...
NOV 20, 2019
Technology
NOV 20, 2019
Machine-Learning and Epigenetics Drug Discovery
Machine learning is known for detecting patterns seen in complex data—such uniqueness has proven it roles in health and medicine. Now, researchers at...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Novel Therapeutic For Eradicating The Flu Virus
Public Health officials have long warned about pandemic pathogens flying fast around the world. One virus already spreads across the globe annually leading...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Possible New Drug Targets for Glioblastoma
Scientists at Karolinska Institutet in Sweden were able to pinpoint 10 tumor-specific potential drug targets for the fatal and incurable brain cancer, glio...
Loading Comments...